Form 4: Aclaris Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Bryan M. Reasons, a director of Aclaris Therapeutics, Inc., exercised stock options and acquired 4,660 shares of common stock on June 1, 2024.
Summary
- On June 1, 2024, Bryan M. Reasons, a director of Aclaris Therapeutics, Inc., exercised restricted stock units, each representing a contingent right to receive one share of common stock.
- This transaction resulted in the acquisition of 4,660 shares of common stock.
- Following the transaction, Reasons directly owns 28,732 shares of Aclaris Therapeutics common stock.
- Reasons has granted power of attorney to Kevin Balthaser and Matthew Rothman of Aclaris Therapeutics, Inc. and Mark Ballantyne, David Brinton and Robin Lee of Cooley LLP to handle SEC filings related to his holdings.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to insider transactions, and does not contain any information that would significantly impact investor sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/28/2024 | Date of execution of Power of Attorney. |
| 06/01/2024 | Date of transaction: exercise of restricted stock units and vesting of shares. |
| 06/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.